Actos News and Research RSS Feed - Actos News and Research

Single injection of protein FGF1 enough to restore blood sugar levels

Single injection of protein FGF1 enough to restore blood sugar levels

In mice with diet-induced diabetes—the equivalent of type 2 diabetes in humans—a single injection of the protein FGF1 is enough to restore blood sugar levels to a healthy range for more than two days. [More]
TSRI scientist receives $2.1M grant to study therapeutic potential of alternatives to current crop of anti-diabetic drugs

TSRI scientist receives $2.1M grant to study therapeutic potential of alternatives to current crop of anti-diabetic drugs

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded $2.1 million from the National Institutes of Health to study the therapeutic potential of safer and more effective alternatives to the current crop of anti-diabetic drugs, which have been limited in their use due to side effects including bone loss and congestive heart failure. [More]
First Edition: April 9, 2014

First Edition: April 9, 2014

Today's headlines include coverage of the release of Medicare billing and utilization data, as well as early insights into who enrolled in health coverage as a result of the health law. [More]
Takeda expands commercial platform in Israel

Takeda expands commercial platform in Israel

Takeda Pharmaceuticals International GmbH today announced further expansion of its commercial platform with the establishment of its wholly-owned subsidiary in Israel. Together with Algeria, Ecuador, Peru, Singapore and Vietnam, Israel is the sixth sales entity Takeda has opened this year to reinforce its platform in growth markets. [More]
FDA grants final approval to Breckenridge’s Pioglitazone Hydrochloride ANDA

FDA grants final approval to Breckenridge’s Pioglitazone Hydrochloride ANDA

Breckenridge Pharmaceutical, Inc. announced today the immediate launch of Pioglitazone Hydrochloride Tablets. The U.S. Food and Drug Administration granted final approval for the Abbreviated New Drug Application (ANDA), which is being manufactured and supplied by Synthon Pharmaceuticals, Inc., and will be available in 15 mg, 30 mg, and 45 mg strengths. [More]
Teva third quarter 2012 net revenues increase 14% to $5.0 billion

Teva third quarter 2012 net revenues increase 14% to $5.0 billion

Teva Pharmaceutical Industries Ltd. today reported results for the quarter ended September 30, 2012. [More]
FDA approves Watson’s generic Actos

FDA approves Watson’s generic Actos

Watson Pharmaceuticals, Inc. today announced that Watson has launched a generic version of Actos (Pioglitazone Hydrochloride 15mg, 30mg and 45mg tablets) after receiving final approval today from the U.S. Food and Drug Administration (FDA). [More]
Mylan Pharmaceuticals receives FDA approval for pioglitazone tablets to treat type 2 diabetes

Mylan Pharmaceuticals receives FDA approval for pioglitazone tablets to treat type 2 diabetes

The U.S. Food and Drug Administration today approved the first generic version of Actos (pioglitazone hydrochloride) tablets. Along with diet and exercise, pioglitazone is used to improve blood glucose control in adults with type 2 diabetes. [More]
Ranbaxy’s generic pioglitazone hydrochloride tablets now available in the U.S.

Ranbaxy’s generic pioglitazone hydrochloride tablets now available in the U.S.

Ranbaxy Pharmaceuticals Inc., a wholly owned subsidiary of Ranbaxy Laboratories Ltd. (RLL), has launched authorized generic pioglitazone hydrochloride tablets in the U.S. market, under an agreement with Takeda Pharmaceuticals U.S.A., Inc. [More]
Study: Diabetes drugs increase patients' risk of bladder cancer

Study: Diabetes drugs increase patients' risk of bladder cancer

A popular class of diabetes drugs increases patients' risk of bladder cancer, according to a new study published online this month in the Journal of the National Cancer Institute. [More]
Popular class of diabetes drugs increase risk for bladder cancer

Popular class of diabetes drugs increase risk for bladder cancer

A popular class of diabetes drugs increases patients' risk of bladder cancer, according to a new study published online this month in the Journal of the National Cancer Institute. [More]
Investigational diabetes drug appears to improve insulin sensitivity without side effects

Investigational diabetes drug appears to improve insulin sensitivity without side effects

Drugs for type 2 diabetes can contribute to weight gain, bone fractures and cardiovascular problems, but in mice, an investigational drug appears to improve insulin sensitivity without those troublesome side effects, researchers at Washington University School of Medicine in St. Louis have shown. [More]
Scientists identify linchpin of fat metabolism

Scientists identify linchpin of fat metabolism

Humans are built to hunger for fat, packing it on during times of feast and burning it during periods of famine. But when deluged by foods rich in fat and sugar, the modern waistline often far exceeds the need to store energy for lean times, and the result has been an epidemic of diabetes, heart disease and other obesity-related problems. [More]
Physician group touts 'high-value' care

Physician group touts 'high-value' care

News reports indicate that the American College of Physicians, which is focusing this message on treatment choices for diabetes and back pain, sees this idea as a way for patients to get the most out of their their health care dollars. [More]
First Edition: June 20, 2012

First Edition: June 20, 2012

Today's headlines include reports that the Veterans' Administration will increase its mental health staffing. [More]
European Commission grants marketing authorization for use of BYETTA with basal insulin

European Commission grants marketing authorization for use of BYETTA with basal insulin

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company announced today that the European Commission has granted marketing authorization to BYETTA (exenatide twice-daily) as an adjunctive therapy to basal insulin, with or without metformin and/or Actos (pioglitazone), for the treatment of type 2 diabetes in adults who have not achieved adequate glycemic control with these agents. [More]
TAK-875 - an emerging therapy for Type 2 diabetes

TAK-875 - an emerging therapy for Type 2 diabetes

In a trial of 426 patients with Type 2 diabetes, TAK-875 reduced blood sugar below a pre-determined level in as much as 48 percent of those receiving it after 12 weeks, compared with 40 percent of those who took glimepiride, the older drug, according to findings published online by The Lancet medical journal. The research was presented in June at the American Diabetes Association’s annual meeting in San Diego. [More]
Weight gain or loss may also depend on medicines taken

Weight gain or loss may also depend on medicines taken

Weight gain or loss may not always be caused by what you eat or how much you exercise. For some, it's the medicines you're taking. [More]
BYETTA-basal insulin combination therapy receives EMA CHMP positive opinion

BYETTA-basal insulin combination therapy receives EMA CHMP positive opinion

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion in the European Union for the expanded use of BYETTA (exenatide twice-daily) as an add-on therapy to basal insulin, with or without metformin and/or Actos (pioglitazone), for the treatment of type 2 diabetes in adults who have not achieved adequate glycemic control with these agents. [More]
Study finds protein's entwined arm movements may control fate of potentially toxic payload

Study finds protein's entwined arm movements may control fate of potentially toxic payload

Like a magician employing sleight of hand, the protein mitoNEET -- a mysterious but important player in diabetes, cancer and aging -- draws the eye with a flurry of movement in one location while the subtle, more crucial action takes place somewhere else. [More]